Slide 1: FY20 Result
Built by physicians for physicians FY20 Result 26 February 2021 1
Slide 2: Innovative provider of cloud-based medical imaging software solutions
Innovative provider of cloud-based medical imaging software solutions IMEXHS LTD | FY20 FINANCIAL RESULTS (ASX:IME) 2
Slide 3: Agenda
Agenda 1. FY20 Result Overview – Dr German Arango, CEO 2. About IMEXHS – Dr German Arango, CEO 3. FY20 Financial Overview – Reena Minhas, CFO 4. Strategy & Outlook – Dr German Arango, CEO 3
Slide 4: FY20 Result Overview
ime x<Hs FY20 Result ove
Slide 5: FY20 Financial Highlights
FY20 Financial Highlights Sales Revenue of ARR of EBITDA of $10.9m $10.1m ($1.3m) Up 41% yoy1, new contract Up 19% yoy, 33% higher on a Improvement of $3.3m, wins & renewals constant currency basis $2.5m on like for like basis3 Recurring revenue of Underlying EBITDA4 of Closing cash of $8.5m $10.8m
Slide 6: FY20 Operational Achievements
FY20 Operational Achievements STRONG MOMENTUM IN GEOGRAPHIC CORE MARKETS EXPANSION ON TRACK • Strong sales of Aquila in the Cloud with 41 • Significant progress in new markets, first US deals signed and ARR contribution of $945k customer signed as at 31 Dec 2020 • Certification in Brazil and Europea
Slide 7: FY20 Software Development
FY20 Software Development • Redesigned Aquila with multi-tenant architecture to create the new business model, Aquila in the cloud • AQUILA 3.0 customized solution enhanced with intuitive interface, improved user experience, advanced tools • Improvement of Alula’s performance with a new streaming te
Slide 8: About IMEXHS
ime xHs About IMEXHS
Slide 9: Expanding global footprint
Expanding global footprint Spain USA 15 countries Mexico >250 sites Honduras El Salvador Nicaragua Australia Costa Rica Colombia >2,100 radiologists Panama Ecuador 23 distributors Peru Brazil Bolivia 1/3 of team in Paraguay software development Chile Uruguay IMEXHS currently operating Argentina Agre
Slide 10: Leading innovator in medical imaging
Leading innovator in medical imaging • Next Generation multi-modality • Scalable, modular HIRUKOTM cloud-based medical imaging software platform provides solutions for all with over 250 sites globally complexity levels • Subscription model with high • Aquila in the Cloud standardised recurring reven
Slide 11: Aquila in the Cloud
Aquila in the Cloud $945k • Aquila in the Cloud, standardised radiology solution, launched in May 2020 41 $675k • Provides small and medium-sized customers with low-cost, rapidly deployed product offering 28 $473k • At 31 Dec 2020, 41 deals signed with ARR $400k contribution of $945k. This has incre
Slide 12: Our competitive advantage
Our competitive advantage ACCESSIBILITY CAPABILITY FLEXIBILITY AFFORDABILITY • Fully web & cloud-based • Single platform and archiving • Multi-modality • Lower cost base than • Teleradiology accessed from system • Scalable modular solutions for competitors any device or browser • Multi-tenant archit
Slide 13: HIRUKO medical imaging platform
HIRUKOTM medical imaging platform Advanced Stella Vital Alma Braviz Post-processing AI 3D ADv 3D Basic Enterprise Aquila Alula Anteros Imaging Radiology Pathology Cardiology Core Platform HIRUKOTM Universal Portals Multi-Tenancy PACS/VNA Viewer Nuance 360 IMEXHS LTD | FY20 FINANCIAL RESULTS (ASX:IME
Slide 14: End-to-end modular imaging solution
End-to-end modular imaging solution Scan scheduled via our platform Uploaded to our platform Archived on our cloud-based platform Manages Billing } 1)Business Intelligence 2)Statistical Data 3. 4. 5. 1. 2. Radiologist Referring Physician Billing Physician Patient has interprets scanned reviews image
Slide 15: Advanced streaming technology
Advanced streaming technology Pixel Info Bandwidth Optimisation Other Info Any web Medical Image VNA Server Rendering Server enabled device IMEXHS LTD | FY20 FINANCIAL RESULTS (ASX:IME) 15
Slide 16: Developing AI capabilities
Developing AI capabilities • Images almost doubled to 940m reflecting full year of Colsubsidio contract Number of Images Stored (m) 940 • Important test bed for the development and training of AI tools • Developed Stella AI which identifies normal and 488 pathological radiological patterns in chest
Slide 17: FY20 Financial Overview
ime x<Hs FY20 Financial oversen|
Slide 18: Strong growth in sales revenue
Strong growth in sales revenue Sales Revenue ($m) • Revenue of $10.9m, up 41% (59% on a constant currency (incl constant currency impact) basis) due to new contract wins and renewals • Recurring revenue of $8.5m, up 29% (45% on a constant currency basis) $1.3m $2.4m • Strategic focus on driving subs
Slide 19: Strong growth in ARR
Strong growth in ARR Annualised Recurring Revenue 20162017201820192020 • Annual Recurring Revenue (ARR) of 12 $10.1m, up 19% yoy (33% on constant currency basis) 10 8 • Recent contract wins include Gables Radiology in the US, Keralty 6 (Colombia), and Laboratorios Santa $m 4 Maria (Mexico) 2 • Contr
Slide 20: Underlying EBITDA Improvement
Underlying EBITDA Improvement #039;000 FY20 FY19 Var Var % Recurring revenue contracts 8,543 6,603 1,940 29% • Total revenue of $11.0m, up 42% Other sales revenue 2,371 1,124 1,247 111% Other revenue 88 12 76 644% • Operating expenses of $14.5m Total revenue 11,002 7,739 3,263 42% reflect increased inv
Slide 21: Balance Sheet
Balance Sheet #039;000 Dec 20 Dec 19 Cash 10,796 7,150 Trade & other receivables 5,056 3,654 • Cash on hand of $10.8m Inventories 390 107 Current assets 16,243 10,911 • Increase in Trade & Other Receivables due to strong sales in the Non-current assets 4,562 3,887 last quarter Total assets 20,804 14,79
Slide 22: Summary Cash Flow
Summary Cash Flow #039;000 FY20 FY19 Net cash used in operating activities (1,467) (4,090) • From 1 Jan 2020, IMEXHS Net cash used in investing activities (2,187) (2,460) capitalised software development Net cash flow from financing activities 7,405 11,280 expenses resulting in lower Effects of exchang
Slide 23: Strategy & Outlook
imexHs Strategy & outook
Slide 24: Industry Trends: Healthcare IT sector
INDUSTRY TRENDS: Healthcare IT sector Increasing use of Large, rapidly radiological Chronic global Shift from client growing but highly Increased proportion techniques in wider radiologist shortage server architecture to fragmented global of the value chain clinical applications, driving demand for
Slide 25: 2021 Product Roadmap
2021 Product Roadmap AQUILA 4.0 with new Alula Marketplace, the Other medical verticals AI Algorithms features and functions world’s first dedicated • Dental Imaging • Automatic detection and orientated to US and pathology marketplace platform segmentation of lung Australian markets workflow program
Slide 26: FY21 Outlook
FY21 Outlook Aquila in the Cloud (AiC) – Leverage 2021 trading to date in line with distribution partners to convert strong Company expectations interest across all markets Improved outlook for key markets US – build presence with AiC offering despite second waves of COVID-19 and via online marketpl
Slide 27: Appendix
ime x<Hs sapere
Slide 28: Built by physicians for physicians
Built by physicians for physicians 2012 2016 2018 2020 Founded in Colombia Release zero IMEXHS lists Launched Aquila in by two Professors of footprint WEB on ASX the Cloud, open US office, certification Neuroradiology & viewer in Brazil and EU, radiology software new partners engineer 2015 2017 2019
Slide 29: Significant global opportunity
Significant global opportunity • Global market is valued at US$2.7bn RIS/PACS • Estimated Put 3to growpoints bullet at 7.4% CAGR 2018 US$2.7bn • and text here Projected global RIS/PACS market of $5.0bn in 2027 2027 US$5.0bn • This only captures Radiology Imaging Systems • Further upside from other m
Slide 30: Our customers
Our customers IMEXHS LTD | FY20 FINANCIAL RESULTS (ASX:IME) 30
Slide 31: Glossary
Glossary Artificial intelligence (AI) tools aid the Medical verticals are market segments Streaming technology transfers medical interpretation of radiological images that refer to specific diagnostic images from our VNA to our Web Viewer, which require access to large image departments within hospi
Slide 32: Thank You
Thank You WWW.IMEXHS.COM 32
Slide 33: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co